For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

European shares closed higher on Tuesday, buoyed by better-than-expected corporate earnings and renewed optimism that the ...

Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Not anytime soon, according to the latest quarterly numbers from Palantir . The software analytics company has been identified by S ...

UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from ...

EMCOR Group delivered above-expectations results in Q2 2025 with the management raising its full-year guidance. Read more on ...

This maker of weight-loss drugs saw its share price zoom and then crash. The CEO has been replaced. The incoming boss will ...